Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016 (2016), Article ID 1473612, 6 pages
http://dx.doi.org/10.1155/2016/1473612
Clinical Study

Myo-Inositol in the Treatment of Teenagers Affected by PCOS

Archil Khomasuridze Institute of Reproductology, 0112 Tbilisi, Georgia

Received 3 June 2016; Revised 28 July 2016; Accepted 1 August 2016

Academic Editor: Fabio Facchinetti

Copyright © 2016 Lali Pkhaladze et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. V. Zborowski, J. A. Cauley, E. O. Talbott, D. S. Guzick, and S. J. Winters, “Bone mineral density, androgens, and the polycystic ovary: the complex and controversial issue of androgenic influence in female bone,” Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 10, pp. 3496–3506, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. F. J. Broekmans, E. A. H. Knauff, O. Valkenburg, J. S. Laven, M. J. Eijkemans, and B. C. J. M. Fauser, “PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors,” British Journal of Obstetrics and Gynaecology, vol. 113, no. 10, pp. 1210–1217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Hassan and C. M. Gordon, “Polycystic ovary syndrome update in adolescence,” Current Opinion in Pediatrics, vol. 19, no. 4, pp. 389–397, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Livadas and E. Diamandi-Candarakis, “Policistic ovary syndrome: definitions, phenotipes and diagnostic approach,” in Polycystic Ovary Syndrome. Novel Insights into Causes and Therapy, D. Macut, M. Pfeifer, B. O. Yildiz, and E. Diamanti-Kandarakis, Eds., vol. 40 of Fronties on Hormone Research, pp. 1–21, Karger, Basel, Switzerland, 2013. View at Google Scholar
  5. J. Vrbikova and V. Hainer, “Obesity and polycystic ovary syndrome,” Obesity Facts, vol. 2, no. 1, pp. 26–35, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. V. L. Nelson, K.-N. Qin, R. L. Rosenfield et al., “The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 12, pp. 5925–5933, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. P. M. Vuguin, “Interventional studies for polycystic ovarian syndrome in children and adolescents,” Pediatric Health, vol. 4, no. 1, pp. 59–73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon, “Cardiovascular actions of insulin,” Endocrine Reviews, vol. 28, no. 5, pp. 463–491, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Hardiman, O. S. Pillay, and W. Atiomo, “Polycystic ovary syndrome and endometrial carcinoma,” The Lancet, vol. 361, no. 9371, pp. 1810–1812, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Harwood, P. Vuguin, and J. DiMartino-Nardi, “Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth,” Hormone Research, vol. 68, no. 5, pp. 209–217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. K. E. S. Salley, E. P. Wickham, K. I. Cheang, P. A. Essah, N. W. Karjane, and J. E. Nestler, “Position statement: glucose intolerance in polycystic ovary syndrome—a position statement of the androgen excess society,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 12, pp. 4546–4556, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Rossi, S. Sukalich, J. Droz et al., “Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome,” The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 12, pp. 4780–4786, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. L. J. Moran, G. D. Brinkworth, and R. J. Norman, “Dietary therapy in polycystic ovary syndrome,” Seminars in Reproductive Medicine, vol. 26, no. 1, pp. 85–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Borzdag and B. O. Yildiz, “Combined oral contraceptives in polycystic ovary syndrome—indications and caution,” in Polycystic Ovary Syndrome. Novel Insights into Causes and Therapy, D. Macut, M. Pfeter, B. O. Yildiz, and E. Diamanti-Kandaratis, Eds., vol. 40 of Frontiers of Hormone Research, pp. 115–118, Karger, Basel, Switzerland, 2013. View at Google Scholar
  15. R. Mathur, O. Levin, and R. Azziz, “Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome,” Therapeutics and Clinical Risk Management, vol. 4, no. 2, pp. 487–492, 2008. View at Google Scholar · View at Scopus
  16. L. Harborne, R. Fleming, H. Lyall, J. Norman, and N. Sattar, “Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome,” The Lancet, vol. 361, no. 9372, pp. 1894–1901, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. Practice Committee of the American Society for Reproductive Medicine, “Use of insulin-sensitizing agents in the treatment of polycystic ovary syndrome,” Fertility and Sterility, vol. 90, no. 5, pp. 69–73, 2008. View at Google Scholar
  18. G. W. Bates and N. S. Whitworth, “Effect of body weight reduction on plasma androgens in obese, infertile women,” Fertility and Sterility, vol. 38, no. 4, pp. 406–409, 1982. View at Publisher · View at Google Scholar · View at Scopus
  19. A. D. Genazzani, C. Lanzoni, F. Ricchieri, and V. M. Jasonni, “Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 24, no. 3, pp. 139–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. E. Nestler, D. J. Jakubowicz, P. Reamer, R. D. Gunn, and G. Allan, “Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome,” The New England Journal of Medicine, vol. 340, no. 17, pp. 1314–1320, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Carlomagno, V. Unfer, and S. Roseff, “The D-chiro-inositol paradox in the ovary,” Fertility and Sterility, vol. 95, no. 8, pp. 2515–2516, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Bevilacqua, G. Carlomagno, S. Gerli et al., “Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology-assisted reproduction technology,” Gynecological Endocrinology, vol. 31, no. 6, pp. 441–446, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Facchinetti, M. Bizzarri, S. Benvenga et al., “Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 195, pp. 72–76, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Papaleo, V. Unfer, J.-P. Baillargeon et al., “Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction,” Gynecological Endocrinology, vol. 23, no. 12, pp. 700–703, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Costantino, G. Minozzi, F. Minozzi, and C. Guaraldi, “Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial,” European Review for Medical and Pharmacological Sciences, vol. 13, no. 2, pp. 105–110, 2009. View at Google Scholar · View at Scopus
  26. T. Tang, J. M. Lord, R. J. Norman, E. Yasmin, and A. H. Balen, “Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility,” Cochrane Database of Systematic Reviews, vol. 20, no. 1, Article ID CD003053, 2010. View at Google Scholar · View at Scopus
  27. E. Papaleo, V. Unfer, J. P. Baillargeon, and T. T. Chiu, “Contribution of myo-inositol to reproduction,” European Journal of Obstetrics Gynecology & Reproductive Biology, vol. 147, no. 2, pp. 120–123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. B. C. Fauser, B. C. Tarlatzis, R. W. Rebar et al., “The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS),” Human Reproduction, vol. 19, pp. 41–47, 2004. View at Google Scholar
  29. A. D. Genazzani, A. Prati, G. Despini, and E. Chierchia, “Insulin resistance and PCOS as metabolic disease,” Giornale Italiano di Ostetricia e Ginecologia, vol. 37, no. 1, pp. 11–17, 2015. View at Google Scholar
  30. E. Diamanti-Kandarakis, C. Christakou, E. Palioura, E. Kandaraki, and S. Livadas, “Does polycystic ovary syndrome start in childhood?” Pediatric Endocrinology Reviews, vol. 5, no. 4, pp. 904–911, 2008. View at Google Scholar · View at Scopus
  31. A. Tolino, V. Gambardella, C. Caccavale et al., “Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome,” European Journal of Obstetrics and Gynecology and Reproductive Biology, vol. 119, no. 1, pp. 87–93, 2005. View at Publisher · View at Google Scholar
  32. B. M. Schroeder, “ACOG releases guidelines on diagnosis and management of polycystic ovary syndrome,” American Family Physician, vol. 67, no. 7, pp. 1619–1622, 2003. View at Google Scholar · View at Scopus
  33. B. C. J. M. Fauser, B. C. Tarlatzis, R. W. Rebar et al., “Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group,” Fertility and Sterility, vol. 97, no. 1, pp. 28–38, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Borzdag and B. Yildiz, “Combined oral contraceptives in polycystic ovary syndrome—indications and caution,” in Polycystic Ovary Syndrome. Novel Insights into Causes and Therapy. Fronties of Hormonal Research, D. Macut, M. Pfeier, B. Yildiz, and E. Diamanti-Kandarakis, Eds., vol. 40, pp. 123–125, Karger, Basel, Switzerland, 2013. View at Google Scholar
  35. M. Minozzi, D. Costantino, C. Guaraldi, and V. Unfer, “The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome,” Gynecological Endocrinology, vol. 27, no. 11, pp. 920–924, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Minozzi, G. D'Andrea, and V. Unfer, “Treatment of hirsutism with myo-inositol: a prospective clinical study,” Reproductive BioMedicine Online, vol. 17, no. 4, pp. 579–582, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Weenen, J. S. E. Laven, A. R. M. von Bergh et al., “Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment,” Molecular Human Reproduction, vol. 10, no. 2, pp. 77–83, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Pigny, S. Jonard, Y. Robert, and D. Dewailly, “Serum anti-Müllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 3, pp. 941–945, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Dewailly, H. Gronier, E. Poncelet et al., “Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries,” Human Reproduction, vol. 26, no. 11, pp. 3123–3129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. Z. Kamenov, G. Kolarov, A. Gateva, G. Carlomagno, and A. D. Genazzani, “Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance,” Gynecological Endocrinology, vol. 31, no. 2, pp. 131–135, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. V. Unfer, G. Carlomagno, P. Rizzo, E. Raffone, and S. Roseff, “Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial,” European Review for Medical and Pharmacological Sciences, vol. 15, no. 4, pp. 452–457, 2011. View at Google Scholar · View at Scopus
  42. C. Christakou, A. Kollias, C. Piperi, I. Katsikis, D. Panidis, and E. Diamanti-Kandarakis, “The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers,” Hormones, vol. 13, no. 4, pp. 488–497, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Gerli, E. Papaleo, A. Ferrari, and G. C. Di Renzo, “Randomized, double blind placebo-controlled trial: effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS,” European Review for Medical and Pharmacological Sciences, vol. 11, no. 5, pp. 347–354, 2007. View at Google Scholar · View at Scopus
  44. S. Nader, M. G. Riad-Gabriel, and M. F. Saad, “The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 9, pp. 3074–3077, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. L. C. Morin-Papunen, I. Vauhkonen, R. M. Koivunen, A. Ruokonen, H. K. Martikainen, and J. S. Tapanainen, “Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 9, pp. 3161–3168, 2000. View at Google Scholar · View at Scopus
  46. K. Elter, G. Imir, and F. Durmusoglu, “Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study,” Human Reproduction, vol. 17, no. 7, pp. 1729–1737, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Morin-Papunen, I. Vauhkonen, R. Koivunen, A. Ruokonen, H. Martikainen, and J. S. Tapanainen, “Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study,” The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 1, pp. 148–156, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Guido, D. Romualdi, M. Giuliani et al., “Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2817–2823, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. K. M. Hoeger, L. Kochman, N. Wixom, K. Craig, R. K. Miller, and D. S. Guzick, “A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study,” Fertility and Sterility, vol. 82, no. 2, pp. 421–429, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Hoeger, K. Davidson, L. Kochman, T. Cherry, L. Kopin, and D. S. Guzick, “The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 11, pp. 4299–4306, 2008. View at Publisher · View at Google Scholar · View at Scopus